Design: In vitro mechanistic study with chromatin immunoprecipitation and transcriptomics
Population: Primary human keratinocytes stimulated with TNF and IL-17
Primary outcome: BET protein recruitment to IL6 and IL8 promoters and resulting gene expression
Effect: I-BET151 blocked BRD2/3/4 recruitment and cytokine gene induction; BRD4 and p65 enriched preferentially at the IL6 promoter

Biologics in psoriasis work by removing a cytokine from the system. This study asks what the keratinocyte does with the cytokine signal once it arrives, and whether that step is itself druggable.

Primary human keratinocytes were stimulated with TNF and IL-17 — the combination that drives the psoriatic plaque — and treated with the BET inhibitor I-BET151. The stimulus produced histone hyperacetylation and recruited the bromodomain proteins BRD2, BRD3 and BRD4 to the IL-6 and IL-8 promoters, with RNA polymerase II activation tracking the rise in transcription. I-BET151 blocked all of it. Notably, BRD4 and the NF-kappa-B subunit p65 were enriched more at the IL-6 promoter than at IL-8, suggesting the two inflammatory genes are not read by the same machinery. Transcriptomics showed the inhibitor also modulated cell cycle, apoptosis and proliferation genes that overlap with psoriasis-associated genes.

The clinical relevance is a long way off and worth stating plainly: BET inhibitors have been difficult to develop systemically because they hit proliferating tissue broadly, and the overlap with cell cycle genes seen here is the same property that causes the toxicity. If this pathway reaches the clinic in skin it will most plausibly be topical.

No change to biologic or systemic selection in psoriasis.
Keep screening for psoriatic arthritis at review — it remains the most missed comorbidity.
Treat this as target biology, not as an argument for any available drug.
Note the IL-6 finding is mechanistic; IL-6 blockade has not performed well in psoriasis clinically.

Why it matters

It moves the drug target from the cytokine in the blood to how the skin cell reads it.

The statistics, in plain English

Everything reported is from cultured cells: chromatin immunoprecipitation, gene expression and transcriptomics. There is no clinical endpoint, no PASI, no patient. Overlap between the genes an inhibitor modulates and 'psoriasis-associated genes' is a hypothesis-generating observation — gene lists of that kind overlap readily by chance when both are large.